Sponsored Links 
Depomed Poised for a Run
Depomed, Inc. (DEPO - Analyst Report) has risen more than 32% in the last three months to trade near its 52-week high of $4.52. Its deal with CVS Caremark (CVS - Analyst Report) can help in expanding distribution of diabetes drug Glumzeta. The Zacks #1 (Strong Buy) company already has two successful drugs in the market, and looks attractive to shareholders at its current price. Analysts expect a loss of $0.50 per share in 2008, less than their prior forecast of $0.89.
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Loading Stories...Related Content
Loading Stories...Most Popular on Zacks.com
0.00 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 25, 2009 06:03 am ET |
-17.24
Sponsored Links
[CLICK TO CLOSE X]